Navigation Links
Lifeline Biotechnologies and Depository Trust Company
Date:9/30/2011

RENO, Nev., Sept. 30, 2011 /PRNewswire/ -- Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) announced today that the Company continues efforts to reestablish DTC services.

Jim Holmes, Lifeline's CEO said "While our efforts have continued to reestablish DTC's services to the Company we have not been successful.  We now are considering alternatives should the circumstances not change.

The value of Lifeline is not reflected in the current lack of liquidity (low per share market price and low daily volume of shares traded).  Lifeline's investment in First Warning Systems has not diminished; in fact, First Warning's value has appreciated as established milestones have been achieved.  Our focus in First Warning is preparation for the final round of clinical trials estimated to commence in the latter half of 2012.   At this time, our best estimate for trial completion is late 2013. The trails must be successfully completed before our FDA medical device marketing application is submitted in the U.S."

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.

CONTACT: Lifeline Biotechnologies, Inc.
Jim Holmes, 775-326-9614    Email: Jholmes@lbti.com    website: www.lbti.com


'/>"/>
SOURCE Lifeline Biotechnologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc.
2. Lifeline Skin Care™ Selects Click Here, Inc., Richards Partners
3. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
4. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
5. Benjamin Custodio Joins Millennium Biotechnologies to Expand International Sales
6. Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease
7. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
8. Commonwealth Biotechnologies Presents Data at Forensic Sciences Meeting Confirming Benefits of ZyGEMs DNA Extraction Technology
9. Andre Marion Joins Microchip Biotechnologies Board of Directors
10. TriLink BioTechnologies to Sponsor GIVING HUNGER THE BLUES, a Benefit Concert to Help Alleviate Hunger in San Diego County
11. TriLink BioTechnologies, Inc. Relaunches Oligonucleotide Radiolabeling Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... 05, 2016 , ... This composition patent, U.S. Patent No. ... The composition claims are not limited to any particular process to make or ... carbon fibers, graphene, and other materials. A continuation application, U.S. Patent App. ...
(Date:12/5/2016)... , Dec. 5, 2016  Renova™ Therapeutics, ... congestive heart failure and other chronic diseases, announced ... the company as Chief Financial Officer (CFO), effective ... with 20 years of experience in financial management ... biotech and software companies. Most recently, Ms. Bovenizer ...
(Date:12/5/2016)... , December 5, 2016 The ... with almost $108 billion of revenue and some $890 ... were spent on global biopharmaceuticals, and this figure is ... Stock-Callers.com has lined up these four equities for assessment: ... Pharmaceuticals Inc. (NASDAQ: ACAD ), Acorda Therapeutics ...
(Date:12/2/2016)... ... ... In anticipation of AxioMed’s exclusive cleanroom manufacturing facility in ... Lubinski will be traveling to Switzerland from December 5-10. Mr. Lubinski will meet ... to discuss the benefits of a viscoelastic disc. AxioMed received CE mark in ...
Breaking Biology Technology:
(Date:11/30/2016)... SAN FRANCISCO and WARSAW, Poland , Nov. 30, 2016 ... sleeping. It is one of the most crucial aspects of recovery so we need ... host of serious health risks, including heart problems, high blood pressure, stroke, diabetes, and ... family and friends sleep and find a Christmas present that could help them to ... ...
(Date:11/29/2016)... Lithuania , Nov. 29, 2016 /PRNewswire/ ... biometric identification and object recognition technologies, today ... (SDK) for fingerprint recognition solutions that run ... a fingerprint template using less than 128KB ... in compact devices that have limited on-board ...
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
Breaking Biology News(10 mins):